Health Canada Posts Type II Recall of Two IMAAVY Lots Over Possible Glass Particles

Health Canada has posted a national Type II recall for two lots of IMAAVY solution because the affected units may contain glass particles. The recall is directed to healthcare establishments and involves Janssen Inc. product distributed across Canada.

Affected product

Health Canada classifies the action as a Type II recall. The federal notice identifies the issue as product quality and says the affected lots may contain glass particles.

Why this matters for pharmacy teams

The recall depth is healthcare establishments, making lot-level checks especially important for hospital, clinic, infusion and other institutional inventories. Teams should follow their local recall procedure and the recalling firm's instructions rather than relying on the product name alone.

Health Canada advises people to verify whether their product is affected, consult a healthcare provider about health concerns, contact the recalling firm with recall questions, and report suspected side effects or other product-quality complaints.

Practice guidance for pharmacists

• Search all active, reserve and satellite inventory for DIN 02563509 and compare lot numbers exactly.
• Quarantine units from lots JNYJ1202 and JNYJ1206 according to your organization's recall procedure; do not return them to usable stock.
• Check recent dispensing, preparation and administration records to determine whether affected lots may have reached a patient-care area.
• Coordinate with procurement, nursing and affected clinical services so replacement-stock and continuity plans are clear.
• Document the reconciliation and follow Janssen's return instructions; report suspected adverse reactions or product-quality complaints to Health Canada.